**Supplementary Table.** Adjusted 5-years risk of non-fatal cardiovascular events or hospitalizations for heart failure attributable to high dp-ucMGP or high sclerostin.

|  |  |  |  |
| --- | --- | --- | --- |
|  | ***Model A*** |  | ***Model B*** |
| HRR (95%CI´s) | *p-value* | HRR (95%CI´s) | *p-value* |
| ***Non-fatal cardiovascular events:***age decademale gendercoronary revascularization current smokingbody mass index ≥30 kg/m2raised blood pressure†LDL ≥1.8 mmol/Lpoor glycemic control**‡**estimated glomerular filtration ≤60 mL/minbrain natriuretic peptide ≥100 ng/mLbeta-blockersRAAS blockersstatinsantidiabeticsdp-ucMGP ≥884 pmol/Lsclerostin ≥589 ng/L | 0.78 (0.61-1.00)0.55 (0.36-0.86) 1.46 (0.46-4.65)1.68 (1.06-2.67)1.00 (0.67-1.50)1.26 (0.84-1.89)1.08 (0.64-1.80)1.12 (0.72-1.74)0.85 (0.54-1.35)1.53 (1.01-2.34)0.69 (0.40-1.20)1.32 (0.80-2.18)0.89 (0.48-1.64)0.97 (0.59-1.60)1.32 (0.81-2.16) | 0.0480.0090.5180.0270.9990.2690.7790.6190.4930.0460.1880.7460.7000.9150.267 |  | 0.77 (0.60-0.99)0.59 (0.37-0.93)1.46 (0.46-4.63) 1.63 (1.04-2.57)0.99 (0.66-1.48)1.33 (0.89-1.99)1.10 (0.66-1.84)1.18 (0.76-1.82)0.91 (0.58-1.42)1.62 (1.07-2.45)0.72 (0.42-1.24)1.34 (0.82-2.21)0.89 (0.48-1.65)0.97 (0.60-1.59)0.81 (0.48-1.36) | 0.0370.0240.5220.0340.9420.1690.7190.4690.6710.0220.2380.2460.7160.9140.424 |
| ***Hospitalization for heart failure :***age decademale gendercoronary revascularization† current smokingbody mass index ≥30 kg/m2raised blood pressure†LDL ≥1.8 mmol/Lpoor glycemic control†estimated glomerular filtration ≤60 mL/minbrain natriuretic peptide ≥100 ng/mLbeta-blockersRAAS blockersstatinsantidiabeticsdp-ucMGP ≥884 pmol/Lsclerostin ≥589 ng/L | 1.40 (0.99-1.97)1.12 (0.65-1.95) 0.43 (0.20-0.92)1.34 (0.65-2.79)0.80 (0.37-1.70)1.71 (1.07-2.74)0.61 (0.37-1.01)1.18 (0.70-1.98)1.58 (0.94-2.65)4.22 (2.41-7.39)0.87 (0.45-1.69)1.58 (0.82-3.04)0.73 (0.36-1.45)1.13(0.66-1.94)1.28 (0.77-2.13) | 0.0560.6840.0290.4320.5560.0260.0540.5290.087<0.00010.6860.1740.3610.6580.347 |  | 1.40 (1.00-1.98)0.90 (0.50-1.64)0.47 (0.22-1.01) 0.92 (0.45-1.91)1.61 (1.01-2.56)0.73 (0.46-1.16)0.61 (0.37-0.99)1.11 (0.66-1.87)1.54 (0.94-2.53)4.13 (2.40-7.08)0.80 (0.42-1.50)1.58 (0.82-3.04)0.73 (0.37-1.44)1.22 (0.71-2.09)1.74 (1.05-2.88) | 0.0530.7350.0540.8320.0460.1880.0460.6900.087<0.00010.4820.1710.3600.4700.031 |

†systolic ≥140 and/or diastolic blood pressure ≥90 mmHg; **‡**fasting glycemia ≥7 mmol/L and/or HBA1c ≥48 mmol/mol;

model A included also treatment with warfarin and both model survey (i.e. EUROASPIRE III or IV);